Perceptive Advisors IKT Position
ActivePerceptive Advisors held their position in Inhibikase Therapeutics, Inc. (IKT) in Q4 2025, holding $11.1M worth of shares across 5,421,568 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
1 other tracked fund also holds IKT.
There is an upcoming Phase 3 readout for IKT-001 in 1171 days (Jun 30, 2029), making the timing of Perceptive's position particularly relevant.
Short interest stands at 18.4% of float with 4.7 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Full company profile →Short Interest
18.4%
4.7 days to cover
Perceptive Advisors IKT Position History
Frequently Asked Questions
Does Perceptive Advisors own IKT?
Yes. As of Q4 2025, Perceptive Advisors holds 5,421,568 shares of Inhibikase Therapeutics, Inc. (IKT) valued at $11.1M. This data comes from their SEC 13F filing.
How many hedge funds own IKT?
2 specialist biotech hedge funds currently hold IKT, including Commodore Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy IKT?
Perceptive Advisors's position in IKT was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's IKT position increasing or decreasing?
Perceptive Advisors held their IKT position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IKTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →